Disclosed are methods for modulating splicing of Ataxin 3 mRNA in an animal with modified oligonucleotides. Such compounds and methods are useful to treat, prevent, or ameliorate spinocerebellar ataxia type 3 (SCA3) in an individual in need thereof.

The present invention relates to the field of biochemistry, more particularly to proteomics, more particularly to protein sequencing, even more particularly to single molecule peptide sequencing. The invention discloses methods for single molecule protein sequencing and/or amino acid identification using cleavage inducing agents which are not specific for one particular amino acid, cleave polypeptides step by step from the N-terminus onwards and provide information on the identity of the cleaved amino acids based on the reaction kinetics.

Provided herein are prodrug compounds of Formula (I) and compositions thereof useful in methods for adoptive cell therapy.

##STR00001##

Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.

The present invention relates to flavour generation. In particular the invention relates to a method for flavour generation in a heat-treated food product using a prolidase enzyme. The invention also relates to a heat-treated food product prepared according to the method of the invention.

Microbial cell lines suitable for industrial-scale production of organic acids and methods of making and isolating such cell lines.

Disclosed are compositions and methods for treating neurological diseases, disorders, and injuries in a subject in need thereof. Particularly disclosed are compositions and methods for treating neurological diseases, disorders, and injuries that are associated with upper motor neurons in a subject in need thereof in which methods expression of ubiquitin carboxyl hydrolase ligase 1 (UCHL1) is modulated in the subject, for example, via gene therapy being administered to the subject in order to express UCHL1 in upper motor neurons of the subject. Also disclosed are expression vectors comprising the UCHL1 promoter operably linked to a nucleic acid encoding a therapeutic gene product.

The present disclosure relates to genetically modified non-human animals (e.g., genetically-modified mice or rodents) that express a hACE2 and/or hTMPRRS2 under control of the mouse promoter and the genetically modified non-human animal does not express native ACE2 and/or hTMPRRS2. The present disclosure also relates to methods of generating the genetically-modified animals (e.g., genetically modified mice or rodents), and methods of using the genetically modified non-human animals (e.g., genetically modified mice or rodents) described herein.

Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologically active fragment thereof. Such methods and compositions may be employed to reduce, prevent, degrade and/or eliminate amyloid formation in the lysosome and/or extracellularly.

Described herein are methods for selectively cleaving the C-terminal amino acid of a peptide or protein. The methods described herein may be applicable for, for example, single-molecule peptide or protein sequencing.